TIDMDEMG
RNS Number : 9529Z
Deltex Medical Group PLC
27 May 2021
27 May 2021
Deltex Medical Group plc ("Deltex Medical" or the "Group")
Chairman's statement to the Annual General Meeting
Director changes
Deltex Medical Group plc (AIM: DEMG), the global leader in
oesophageal Doppler monitoring, today publishes an AGM statement
and announces the appointment of a new Finance Director.
AGM statement
At today's Annual General Meeting, the Group's Chairman, Nigel
Keen, will make the following statement :
"There are encouraging signs that around the world the volume of
elective surgical procedures, which represent our core market, is
climbing.
The Group's activity levels in the UK and the USA continue to
face headwinds as we are still limited to the extent that we can
get our clinical educators into hospitals.
Our International business is showing signs of increased
activity levels as some of our distributors are beginning to
increase the volume of orders significantly as compared to the
prior year."
Director changes
As previously outlined in the announcement of the 2020 results
on 22 April 2021, David Moorhouse is retiring as Group Finance
Director and from the Board at the end of the AGM today.
Natalie Wettler, currently Group Financial Controller, is being
promoted to Group Finance Director with effect from the end of the
AGM.
Natalie held a number of senior roles in the Group's finance
department between 2011 and 2016, and we were delighted when she
agreed to rejoin the Group in January 2020 as Group Financial
Controller.
Nigel Keen, Chairman of Deltex Medical, said:
"As the number of elective procedures begins to increase, we are
looking forward to being able to get our clinical educators back
into hospitals to assist clinicians with the use of Deltex
Medical's haemodynamic monitoring technology. This will help
hospitals reduce the level of avoidable complications and also help
the Group drive the level of revenues derived from each
hospital."
"I would like to thank David Moorhouse for all his hard work and
wise counsel as Group Finance Director over the last 18 months. On
behalf of the Board, I would wish him an enjoyable and relaxed
retirement."
"The Board is delighted with the internal promotion of Natalie
Wettler to Group Finance Director. She has a very detailed
understanding of the Group's financial systems and structures, and
we look forward to working closely with her."
*********************
The following information in relation to the appointment of Mrs.
Natalie Emilia Wettler (aged 38) (née Natalie Emilia Antkowiak) is
disclosed in accordance with Schedule 2(g) of the AIM Rules for
Companies.
Current directorships Past directorships held within
the last five years
None. None.
-------------------------------
Mrs. Wettler does not have an interest in any ordinary shares of
1 pence each ("Shares") in the capital of Deltex Medical and holds
2,725,000 options over Shares.
There is no further information to be disclosed in relation to
Mrs. Wettler's appointment pursuant to AIM Rule 17 or Schedule 2(g)
of the AIM rules for companies.
For further information, please contact:
Deltex Medical Group plc 01243 774 837
Nigel Keen, Chairman investorinfo@Deltexmedical.com
Andy Mears, Chief Executive
Natalie Wettler, Group Finance Director
designate
Arden Partners plc 020 7614 5900
Paul Shackleton info@arden-partners.com
Joint Broker
Turner Pope Investments (TPI) Ltd 0203 657 0050
Andy Thacker info@turnerpope.com
James Pope
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring
technologies which are primarily used in critical care and general
surgical procedures. Deltex Medical's proprietary oesophageal
Doppler monitoring ("ODM") (TrueVue Doppler) measures blood flow
velocity in the central circulation in real time. Minimally
invasive, easy to set-up and quick to focus, the technology
generates a low-frequency ultrasound signal which is highly
sensitive to changes in blood flow and measures such changes in
'real time'. Deltex Medical is the only company in the enhanced
haemodynamic monitoring space to have built a robust and credible
evidence base demonstrating both the clinical and economic benefits
of its core technology: TrueVue Doppler. This technology has been
proven in a wide range of clinical trials to reduce complications
suffered by patients after surgery and consequently can save
hospitals money.
Deltex Medical's TrueVue System on the CardioQ-ODM+ monitor
platform now provides clinicians with two further advanced
haemodynamic monitoring technologies. TrueVue Impedance is an
entirely non-invasive monitoring technology which transmits low
magnitude, high frequency electrical signals through the thorax and
measures the changes to this signal when the heart pumps blood.
TrueVue PressureWave uses the peripheral blood pressure signal
analysis to give doctors information on changes in the circulation
and is particularly suited to monitoring lower risk or
haemodynamically stable patients. The next generation TrueVue
monitor is targeted for release in Q4 2021.
Group goal
Haemodynamic management is now becoming widely accepted as a
vital part of the anaesthesia protocols for surgical patients, as
well as treating ventilated intensive care patients, including
ventilated COVID-19 patients. Consequently, the Group's focus is on
maximising value from the opportunities associated with: the CV-19
pandemic; the elective surgery backlog; and the higher profile of
haemodynamic monitoring which has arisen from the recent
consolidation in the sector. The Group aims to provide clinicians
with a modern, next generation, single 'haemodynamic workstation'
platform which offers them a range of technologies from simple to
sophisticated to be deployed according to the patient's clinical
condition as well as the skill and expertise of the user. Doing
this will enable the Group to partner with healthcare providers to
support modern haemodynamic management across the whole
hospital.
The Group is currently in the implementation phase of achieving
this goal in a number of territories worldwide, operating directly
in the UK and the USA, and via agreements with approximately 40
distributors overseas.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGMUNVNRABUVUAR
(END) Dow Jones Newswires
May 27, 2021 02:00 ET (06:00 GMT)
Deltex Medical (LSE:DEMG)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Deltex Medical (LSE:DEMG)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024